... Pharmaceuticals Inc. said Wednesday the Food and Drug Administration approved its generic version of Dey LP's respiratory condition treatment DuoNeb. ...
DuoNeb had annual sales of about $265 million in the United States for the 12 months ended September 30. FinancialWire is an independent, proprietary news ...
TA said the US Food and Drug Administration gave final approval for a generic version of Dey LP's bronchodilator, DuoNeb. Shipment of the inhalation ...
The bronchodilator product is a generic version of Dey's DuoNeb dual-therapy nebulizer for patients suffering from bronchospasms. DuoNeb generated US sales ...
Dey's DuoNeb is delivered via nebulizers. DuoNeb is used as a treatment for COPD chronic obstructive pulmonary disease. The brand product had annual sales ...
... and Drug Administration granted final approval for its abbreviated new drug application to market a generic version of Dey LP's bronchodilator, DuoNeb. ...
... its generic version of Dey’s bronchodilator, DuoNeb® (Albuterol Sulfate and Ipratropium Bromide) Inhalation Solution, 3 mg (0.083%) and 0.5 mg (0.017%). ...
... Company's Abbreviated New Drug Application (ANDA) to market its generic version of Dey's bronchodilator, DuoNeb(R) Inhalation Solution, 3 mg and 0.5 mg. ...
... generic version of Dey's bronchodilator, DuoNeb(R) (Albuterol Sulfate and Ipratropium Bromide) Inhalation Solution, 3 mg (0.083%) and 0.5 mg (0.017%). ...
... and Drug Administration granted final approval for its abbreviated new drug application to market a generic version of Dey LP's bronchodilator, DuoNeb. ...